InformaSeq’s high detection rates (sensitivity) and low false-positive rates (specificity) for common chromosomal and sex aneuploidies provide reliable answers you and your patients can trust.
As with most tests we offer, informaSeq offers choice with three panels. Click any panel name below to view test turnaround times, specimen requirements, specific data about sensitivity, specificity, and PPV, and other clinical details:
- informaSeq: provides risk assessment for the most common autosomal trisomies.
- informaSeq with Y analysis: provides risk assessment for the most common autosomal trisomies, and also provides fetal sex, but not sex chromosome aneuploidies.
- informaSeq with XY analysis: provides risk assessment for the most common autosomal trisomies, sex chromosome aneuploidies, and also provides fetal sex.
Please note: This test does not assess risk for mosaicism, partial trisomies, or translocations. Sex chromosome aneuploidy options may only be ordered for singleton pregnancies.
Additional NIPT options
- MaterniT 21 PLUS: the pioneering NIPT with more than 740,000 tests run1; screens the more well-known trisomies 21, 18, and 13, fetal sex, and (optionally) clinically relevant microdeletions, sex chromosome aneuploidies, and trisomies 16 and 22. Learn more
- MaterniT GENOME: the pioneering genome-wide NIPT; screens all 23 chromosomes, reporting aneuploidies, large deletions and duplications greater than 7 MB in addition to select microdeletions; after more than 35,000 tests resulted, up to 29% of all positive findings could only be detected by MaterniT GENOME methodology as compared to other NIPT offerings.1,2Learn more